Tempest Therapeutics To Go Public Via Millendo Therapeutics Merger
Tempest Therapeutics To Go Public Via Millendo Therapeutics Merger
Tempest治療公司將通過Millendo治療公司合併上市
Millendo Therapeutics Inc (NASDAQ: MLND) has agreed to merge with privately-held Tempest Therapeutics Inc in an all-stock transaction.
- The combined company will operate under the Tempest Therapeutics moniker under ticker 'TPST,' focusing on advancing Tempest's oncology pipeline of small molecule candidates.
- Tempest's oncology pipeline is led by two clinical programs, TPST-1495 and TPST-1120.
- TPST-1495 is currently in Phase 1a/1b dose and schedule optimization study in patients with advanced solid tumors. Topline data is expected by the end of this year. Data from planned monotherapy dose-expansion and combination studies are expected in 2022.
- TPST-1120 has completed monotherapy dose-escalation and is progressing through a combination dose-escalation study with nivolumab.
- Earlier this month, Tempest announced a clinical collaboration with Roche to investigate TPST-1120 in a randomized frontline hepatocellular carcinoma study. Topline data from this study by year-end 2022.
- In support of the merger, Tempest has secured commitments from a syndicate of investors for a $30 million PIPE financing that is expected to close concurrent with the merger's completion.
- The financing and merger are expected to close in the first half of 2021.
- Price Action: MLND shares are trading 12.8% lower at $1.90 in the premarket session on the last check Monday.
Millendo Therapeutics Inc (NASDAQ: MLND) has agreed to merge with privately-held Tempest Therapeutics Inc in an all-stock transaction.
- The combined company will operate under the Tempest Therapeutics moniker under ticker 'TPST,' focusing on advancing Tempest's oncology pipeline of small molecule candidates.
- Tempest's oncology pipeline is led by two clinical programs, TPST-1495 and TPST-1120.
- TPST-1495 is currently in Phase 1a/1b dose and schedule optimization study in patients with advanced solid tumors. Topline data is expected by the end of this year. Data from planned monotherapy dose-expansion and combination studies are expected in 2022.
- TPST-1120 has completed monotherapy dose-escalation and is progressing through a combination dose-escalation study with nivolumab.
- Earlier this month, Tempest announced a clinical collaboration with Roche to investigate TPST-1120 in a randomized frontline hepatocellular carcinoma study. Topline data from this study by year-end 2022.
- In support of the merger, Tempest has secured commitments from a syndicate of investors for a $30 million PIPE financing that is expected to close concurrent with the merger's completion.
- The financing and merger are expected to close in the first half of 2021.
- Price Action: MLND shares are trading 12.8% lower at $1.90 in the premarket session on the last check Monday.
- 合併後的公司將以Tempest Treeutics的名字運營,股票代碼為“TPST”,專注於推進Tempest的小分子候選腫瘤學管道。
- Tempest的腫瘤學流水線由兩個臨牀項目TPST-1495和TPST-1120領導。
- TPST-1495目前正處於1a/1b期進展期實體腫瘤患者的劑量和時間表優化研究中。預計今年年底將公佈背線數據。計劃中的單一療法劑量擴大和聯合研究的數據預計將在2022年公佈。
- TPST-1120已經完成了單一治療劑量遞增,並正在通過與nivolumab的聯合劑量遞增研究取得進展。
- 本月早些時候,Tempest宣佈與羅氏進行臨牀合作,在一項隨機的一線肝細胞癌研究中研究TPST-1120。到2022年底,這項研究的背線數據。
- 為了支持合併,Tempest已經從一個投資者財團獲得了3000萬美元的管道融資承諾,預計將在合併完成的同時完成。
- 融資和合並預計將在2021年上半年完成。
- 價格行動:在週一的盤前交易中,MLND的股價下跌了12.8%,至1.90美元。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
風險及免責聲明
以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
我知道了
風險及免責聲明
以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
我知道了
搶先評論
0 0 0
讚好勁正笑哭社會社會Emm惨惨嬲嬲
輕觸選擇心情
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能,分享給你的好友吧
點擊這裡與好友分享
暫無評論,快來留言吧!